Lucy Day compensation by year
AN2 Therapeutics Summary Compensation Table · all 4 fiscal years held| Component | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Salary | $379,934 | $430,000 | $447,200 | $447,200 |
| Bonus | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $82,500 | $52,545 |
| Option awards | $811,893 | $888,058 | $141,339 | $88,211 |
| Non-equity incentive | $136,776 | $206,400 | $134,160 | $178,880 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $0 | $0 | $7,500 | $7,500 |
| Total | $1,328,603 | $1,524,458 | $812,699 | $774,336 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: AN2 Therapeutics, Inc. DEF 14A filed April 22, 2026, accession 0001193125-26-170314, and prior-year filings. Open the filing on EDGAR.
How this page was built: the AN2 Therapeutics, Inc. filed document, accession 0001193125-26-170314. Every figure is read from that document and cited to the page and table it appears in. Filed April 22, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 46,500 | $53,010 | — |
| RSU | 20,625 | $23,513 | — |
| RSU | 22,588 | $0 | — |
| RSU | 36,578 | $0 | — |
| RSU | 8,837 | $0 | — |
| Option | 71,677 | — | $1.13 |
| Option | 4,125 | — | $17.28 |
| Option | 22,290 | — | $14.29 |
| Option | 28,646 | — | $3.00 |
Per the Outstanding Equity Awards at Fiscal Year-End table in AN2 Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
AN2 Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Eric Easom | President, Chief Executive Officer and Board Chair | $1,382,985 |
| Josh Eizen | Chief Legal Officer and Chief Operating Officer | $807,080 |
| Lucy Day · this page | Chief Financial Officer | $774,336 |
Lucy Day's compensation dossier, AN2 Therapeutics
You have read Lucy Day's totals and holdings. The dossier adds each equity grant AN2 Therapeutics disclosed for Lucy Day and AN2 Therapeutics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full AN2 Therapeutics compensation record
free company briefThis page is one person within AN2 Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order AN2 Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are AN2 Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order ANTX
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.